In the last 5 years, several cases of the drug-induced variant have been reported during treatment of metastatic disease with immunotherapy and targeted therapy.The pathogenesis of targeted therapy-associated Sweet syndrome and its significance as a putative marker of therapeutic response remain to be ascertained. Our patient’s skin eruption was temporally related to the beginning of targeted therapy treatment and meets allthe criteria for the drug-induced form.The molecular mechanisms leading to Sweet syndrome during melanoma could differ depending on the types of treatment.
Scarfì, F., Melotti, B., Veronesi, G., Ravaioli, G.M., Baraldi, C., Lambertini, M., et al. (2019). Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 60(3), e242-e243 [10.1111/ajd.13001].
Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib
Scarfì, Federica
;Ravaioli, Giulia Maria;Baraldi, Carlotta;Lambertini, Martina;Patrizi, Annalisa;Dika, Emi
2019
Abstract
In the last 5 years, several cases of the drug-induced variant have been reported during treatment of metastatic disease with immunotherapy and targeted therapy.The pathogenesis of targeted therapy-associated Sweet syndrome and its significance as a putative marker of therapeutic response remain to be ascertained. Our patient’s skin eruption was temporally related to the beginning of targeted therapy treatment and meets allthe criteria for the drug-induced form.The molecular mechanisms leading to Sweet syndrome during melanoma could differ depending on the types of treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
